A Botticella1, G Defraene2, K Nackaerts3, C Deroose4, J Coolen5, P Nafteux6, B Vanstraelen7, S Joosten8, L A W Michiels8, S Peeters2,7, D De Ruysscher2,9. 1. Department of Oncology, Experimental Radiation Oncology, KU Leuven - University of Leuven, 3000, Leuven, Belgium. angela.botticella@kuleuven.be. 2. Department of Oncology, Experimental Radiation Oncology, KU Leuven - University of Leuven, 3000, Leuven, Belgium. 3. Department of Respiratory Medicine, KU Leuven - University of Leuven, University Hospitals Leuven, 3000, Leuven, Belgium. 4. Nuclear Medicine, KU Leuven - University of Leuven, University Hospitals Leuven, 3000, Leuven, Belgium. 5. Radiology Department, KU Leuven - University of Leuven, University Hospitals Leuven, 3000, Leuven, Belgium. 6. Department of Thoracic Surgery, University Hospitals Leuven, 3000, Leuven, Belgium. 7. Department of Radiation Oncology, University Hospitals Leuven, 3000, Leuven, Belgium. 8. Institute Paramedical Studies, Medical Imaging and Radiotherapeutic Techniques, Fontys University of Applied Science, Eindhoven, The Netherlands. 9. GROW - School for Oncology and Developmental Biology, Department of Radiation Oncology (MAASTRO Clinic), Maastricht University Medical Center, Maastricht, The Netherlands.
Abstract
BACKGROUND: After lung-sparing radiotherapy for malignant pleural mesothelioma (MPM), local failure at sites of previous gross disease represents the dominant form of failure. Our aim is to investigate if selective irradiation of the gross pleural disease only can allow dose escalation. MATERIALS AND METHODS: In all, 12 consecutive stage I-IV MPM patients (6 left-sided and 6 right-sided) were retrospectively identified and included. A magnetic resonance imaging-based pleural gross tumor volume (GTV) was contoured. Two sets of planning target volumes (PTV) were generated for each patient: (1) a "selective" PTV (S-PTV), originating from a 5-mm isotropic expansion from the GTV and (2) an "elective" PTV (E-PTV), originating from a 5-mm isotropic expansion from the whole ipsilateral pleural space. Two sets of volumetric modulated arc therapy (VMAT) treatment plans were generated: a "selective" pleural irradiation plan (SPI plan) and an "elective" pleural irradiation plan (EPI plan, planned with a simultaneous integrated boost technique [SIB]). RESULTS: In the SPI plans, the average median dose to the S‑PTV was 53.6 Gy (range 41-63.6 Gy). In 4 of 12 patients, it was possible to escalate the dose to the S‑PTV to >58 Gy. In the EPI plans, the average median doses to the E‑PTV and to the S‑PTV were 48.6 Gy (range 38.5-58.7) and 49 Gy (range 38.6-59.5 Gy), respectively. No significant dose escalation was achievable. CONCLUSION: The omission of the elective irradiation of the whole ipsilateral pleural space allowed dose escalation from 49 Gy to more than 58 Gy in 4 of 12 chemonaive MPM patients. This strategy may form the basis for nonsurgical radical combined modality treatment of MPM.
BACKGROUND: After lung-sparing radiotherapy for malignant pleural mesothelioma (MPM), local failure at sites of previous gross disease represents the dominant form of failure. Our aim is to investigate if selective irradiation of the gross pleural disease only can allow dose escalation. MATERIALS AND METHODS: In all, 12 consecutive stage I-IV MPM patients (6 left-sided and 6 right-sided) were retrospectively identified and included. A magnetic resonance imaging-based pleural gross tumor volume (GTV) was contoured. Two sets of planning target volumes (PTV) were generated for each patient: (1) a "selective" PTV (S-PTV), originating from a 5-mm isotropic expansion from the GTV and (2) an "elective" PTV (E-PTV), originating from a 5-mm isotropic expansion from the whole ipsilateral pleural space. Two sets of volumetric modulated arc therapy (VMAT) treatment plans were generated: a "selective" pleural irradiation plan (SPI plan) and an "elective" pleural irradiation plan (EPI plan, planned with a simultaneous integrated boost technique [SIB]). RESULTS: In the SPI plans, the average median dose to the S‑PTV was 53.6 Gy (range 41-63.6 Gy). In 4 of 12 patients, it was possible to escalate the dose to the S‑PTV to >58 Gy. In the EPI plans, the average median doses to the E‑PTV and to the S‑PTV were 48.6 Gy (range 38.5-58.7) and 49 Gy (range 38.6-59.5 Gy), respectively. No significant dose escalation was achievable. CONCLUSION: The omission of the elective irradiation of the whole ipsilateral pleural space allowed dose escalation from 49 Gy to more than 58 Gy in 4 of 12 chemonaive MPM patients. This strategy may form the basis for nonsurgical radical combined modality treatment of MPM.
Authors: Emilio Minatel; Marco Trovo; Jerry Polesel; Tania Baresic; Alessandra Bearz; Giovanni Franchin; Carlo Gobitti; Imad Abu Rumeileh; Annalisa Drigo; Paolo Fontana; Vittore Pagan; Mauro G Trovo Journal: Lung Cancer Date: 2013-10-27 Impact factor: 5.705
Authors: William W Chance; David C Rice; Pamela K Allen; Anne S Tsao; Hiral P Fontanilla; Zhongxing Liao; Joe Y Chang; Chad Tang; Hubert Y Pan; James W Welsh; Reza J Mehran; Daniel R Gomez Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-25 Impact factor: 7.038
Authors: Jan P van Meerbeeck; Rabab Gaafar; Christian Manegold; Rob J Van Klaveren; Eric A Van Marck; Mark Vincent; Catherine Legrand; Andrew Bottomley; Channa Debruyne; Giuseppe Giaccone Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Emilio Minatel; Marco Trovo; Jerry Polesel; Imad Abu Rumeileh; Tania Baresic; Alessandra Bearz; Alessandro Del Conte; Giovanni Franchin; Carlo Gobitti; Annalisa Drigo; Andrea Dassie; Vittore Pagan; Mauro G Trovo Journal: J Thorac Oncol Date: 2012-12 Impact factor: 15.609
Authors: A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Péchoux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder Journal: Eur Respir J Date: 2009-08-28 Impact factor: 16.671
Authors: Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass Journal: CA Cancer J Clin Date: 2019-07-08 Impact factor: 508.702
Authors: Christina Leitzen; Timo Wilhelm-Buchstab; Sabina Stumpf; Martina Heimann; David Koch; Christopher Schmeel; Birgit Simon; Susanne Vornholt; Stephan Garbe; Fred Röhner; Felix Schoroth; Hans Heinz Schild; Heinrich Schüller; Thomas Müdder Journal: Strahlenther Onkol Date: 2019-03-26 Impact factor: 3.621